<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02662569</url>
  </required_header>
  <id_info>
    <org_study_id>20120119</org_study_id>
    <secondary_id>2013-000723-14</secondary_id>
    <nct_id>NCT02662569</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia</brief_title>
  <acronym>BERSON</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia (BERSON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous
      evolocumab (AMG 145) in combination with statin therapy (atorvastatin) on percent change from
      baseline in low-density lipoprotein cholesterol (LDL-C) in diabetic adults with
      hyperlipidemia or mixed dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2016</start_date>
  <completion_date type="Actual">December 6, 2017</completion_date>
  <primary_completion_date type="Actual">December 6, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and weeks 10 and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-HDL-C at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B100 at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B100 at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)</measure>
    <time_frame>Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With LDL-C Less Than 70 mg/dL (1.8 mmol/L) at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein(a) at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in HDL-C at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and weeks 10 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">986</enrollment>
  <condition>Diabetes, Hyperlipidemia, Mixed Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Atorvastatin (Q2W)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin (QM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab Q2W + Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab QM + Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Evolocumab Q2W + Atorvastatin</arm_group_label>
    <arm_group_label>Evolocumab QM + Atorvastatin</arm_group_label>
    <other_name>AMG 145</other_name>
    <other_name>Repatha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Administered orally once a day</description>
    <arm_group_label>Atorvastatin (Q2W)</arm_group_label>
    <arm_group_label>Atorvastatin (QM)</arm_group_label>
    <arm_group_label>Evolocumab Q2W + Atorvastatin</arm_group_label>
    <arm_group_label>Evolocumab QM + Atorvastatin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to evolocumab administered by subcutaneous injection</description>
    <arm_group_label>Atorvastatin (Q2W)</arm_group_label>
    <arm_group_label>Atorvastatin (QM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females with type 2 diabetes (receiving pharmacologic treatment for at least
             6 months or longer) with stable diabetes therapy

          -  Lipid-lowering therapy must be unchanged for at least 4 weeks or more

          -  Subjects receiving statin therapy at screening must have a fasting LDL-C of greater
             than or equal to 100 mg/dL

          -  Subjects not receiving statin therapy at screening must have a fasting LDL-C of
             greater than or equal to 130 mg/dL

        Exclusion criteria:

          -  New York Heart Association (NYHA) class III or IV heart failure

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension

          -  Type 1 diabetes or poorly controlled type 2 diabetes

          -  Uncontrolled hypothyroidism or hyperthyroidism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1405BUB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1012AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425ACG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Córdoba</city>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasília</city>
        <state>Distrito Federal</state>
        <zip>71625-009</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goiania</city>
        <state>Goiás</state>
        <zip>74223-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>01244-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>22271-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodstock</city>
        <state>Ontario</state>
        <zip>N4S 5P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7T 2P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Jean sur Richelieu</city>
        <state>Quebec</state>
        <zip>J3A 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>404000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hengyang</city>
        <state>Hunan</state>
        <zip>421001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhuzhou</city>
        <state>Hunan</state>
        <zip>412000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <zip>212001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130033</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>ChangChun</city>
        <state>Jilin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siping</city>
        <state>Jilin</state>
        <zip>136000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>XI An</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linhai</city>
        <state>Zhejiang</state>
        <zip>318000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050012</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlántico</state>
        <zip>08001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlántico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlántico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pasto</city>
        <state>Nariño</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucheon-si, Wonmi-gu</city>
        <zip>420-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-746</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>139-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>117292</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>192289</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196601</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saratov</city>
        <zip>410054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Antalya</city>
        <zip>07058</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34096</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34720</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izmir</city>
        <zip>35000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 20, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2016</study_first_posted>
  <results_first_submitted>November 30, 2018</results_first_submitted>
  <results_first_submitted_qc>January 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2019</results_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 11, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT02662569/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT02662569/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 102 study centers and randomized at 98 centers in Argentina, Brazil, Canada, China, Colombia, France, Republic of Korea, Russian Federation, Turkey, and the United States from 14 April 2016 to 28 July 2017.</recruitment_details>
      <pre_assignment_details>Participants who met eligibility criteria and completed at least 4 weeks of lipid stabilization on atorvastatin 20 mg daily were randomized in a 1:1:2:2 ratio to receive placebo every 2 weeks (Q2W), placebo once a month (QM), evolocumab Q2W, or evolocumab QM. Randomization was stratified by entry statin therapy and geographic region.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo QM</title>
          <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Evolocumab Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Evolocumab QM</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="161"/>
                <participants group_id="P3" count="327"/>
                <participants group_id="P4" count="332"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="160"/>
                <participants group_id="P3" count="325"/>
                <participants group_id="P4" count="332"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="160"/>
                <participants group_id="P3" count="321"/>
                <participants group_id="P4" count="328"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo QM</title>
          <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Evolocumab Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Evolocumab QM</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="166"/>
            <count group_id="B2" value="161"/>
            <count group_id="B3" value="327"/>
            <count group_id="B4" value="332"/>
            <count group_id="B5" value="986"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="327"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="986"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="8.8"/>
                    <measurement group_id="B2" value="61.0" spread="8.8"/>
                    <measurement group_id="B3" value="61.0" spread="8.5"/>
                    <measurement group_id="B4" value="61.6" spread="8.4"/>
                    <measurement group_id="B5" value="61.3" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="327"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="986"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>18 - 64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="206"/>
                    <measurement group_id="B4" value="208"/>
                    <measurement group_id="B5" value="620"/>
                  </measurement_list>
                </category>
                <category>
                  <title>65 - 80 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="124"/>
                    <measurement group_id="B5" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="327"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="986"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="178"/>
                    <measurement group_id="B4" value="190"/>
                    <measurement group_id="B5" value="564"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="142"/>
                    <measurement group_id="B5" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="327"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="986"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="195"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="262"/>
                    <measurement group_id="B4" value="265"/>
                    <measurement group_id="B5" value="791"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="327"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="986"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="166"/>
                    <measurement group_id="B5" value="492"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="140"/>
                    <measurement group_id="B5" value="420"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: Statin Therapy at Study Entry</title>
          <description>Intensive: at least one of the following recorded for the last 4 weeks prior to screening: atorvastatin ≥ 40 mg once daily (QD); rosuvastatin ≥ 20 mg QD; simvastatin ≥ 80 mg QD; any statin (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin) QD plus ezetimibe.
Non-intensive: Participant was taking any dose of a statin at least weekly for the last 4 weeks prior to screening and is not included in the intensive statin usage.
No statin: Participant was not included in the intensive statin usage or non-intensive statin usage.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="327"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="986"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Intensive statin usage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-intensive statin usage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="167"/>
                    <measurement group_id="B4" value="166"/>
                    <measurement group_id="B5" value="496"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No statin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="134"/>
                    <measurement group_id="B5" value="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: Geographic Region</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="166"/>
                    <count group_id="B2" value="161"/>
                    <count group_id="B3" value="327"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="986"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>China</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="150"/>
                    <measurement group_id="B4" value="152"/>
                    <measurement group_id="B5" value="453"/>
                  </measurement_list>
                </category>
                <category>
                  <title>South Korea</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other countries</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="163"/>
                    <measurement group_id="B4" value="167"/>
                    <measurement group_id="B5" value="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-density Lipoprotein Cholesterol (LDL-C) Concentration</title>
          <population>Full analysis set, defined as all randomized participants who received at least 1 dose of study drug (subcutaneous evolocumab or placebo to evolocumab).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="160"/>
                    <count group_id="B3" value="325"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="981"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.2" spread="32.0"/>
                    <measurement group_id="B2" value="91.0" spread="30.7"/>
                    <measurement group_id="B3" value="92.4" spread="33.8"/>
                    <measurement group_id="B4" value="93.5" spread="33.6"/>
                    <measurement group_id="B5" value="92.5" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-high-density Lipoprotein Cholesterol (non-HDL-C) Concentration</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="160"/>
                    <count group_id="B3" value="325"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="981"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119.2" spread="38.2"/>
                    <measurement group_id="B2" value="119.4" spread="36.0"/>
                    <measurement group_id="B3" value="121.3" spread="38.1"/>
                    <measurement group_id="B4" value="121.2" spread="37.0"/>
                    <measurement group_id="B5" value="120.6" spread="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B100 Concentration</title>
          <description>Apolipoprotein B100 is the primary apolipoprotein of low-density lipoprotein cholesterol particles, and plays a role in moving cholesterol around the body.</description>
          <population>Full analysis set with available data</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="162"/>
                    <count group_id="B2" value="158"/>
                    <count group_id="B3" value="325"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="977"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.1" spread="23.1"/>
                    <measurement group_id="B2" value="83.4" spread="22.3"/>
                    <measurement group_id="B3" value="84.8" spread="23.0"/>
                    <measurement group_id="B4" value="84.4" spread="21.8"/>
                    <measurement group_id="B5" value="84.0" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="160"/>
                    <count group_id="B3" value="325"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="981"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.5" spread="38.6"/>
                    <measurement group_id="B2" value="169.3" spread="37.5"/>
                    <measurement group_id="B3" value="167.8" spread="38.9"/>
                    <measurement group_id="B4" value="168.9" spread="38.9"/>
                    <measurement group_id="B5" value="168.2" spread="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol/High-density Lipoprotein Cholesterol(HDL-C) Ratio</title>
          <population>Full analysis set</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="160"/>
                    <count group_id="B3" value="325"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="981"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.717" spread="1.337"/>
                    <measurement group_id="B2" value="3.598" spread="1.071"/>
                    <measurement group_id="B3" value="3.804" spread="1.273"/>
                    <measurement group_id="B4" value="3.725" spread="1.201"/>
                    <measurement group_id="B5" value="3.729" spread="1.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B100/Apolipoprotein A1 Ratio</title>
          <population>Full analysis set with available data</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="162"/>
                    <count group_id="B2" value="158"/>
                    <count group_id="B3" value="325"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="977"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.573" spread="0.192"/>
                    <measurement group_id="B2" value="0.563" spread="0.161"/>
                    <measurement group_id="B3" value="0.601" spread="0.200"/>
                    <measurement group_id="B4" value="0.586" spread="0.185"/>
                    <measurement group_id="B5" value="0.585" spread="0.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lipoprotein (a)</title>
          <population>Full analysis set</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="160"/>
                    <count group_id="B3" value="325"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="981"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.0" spread="90.9"/>
                    <measurement group_id="B2" value="71.8" spread="96.5"/>
                    <measurement group_id="B3" value="65.6" spread="92.5"/>
                    <measurement group_id="B4" value="73.2" spread="95.9"/>
                    <measurement group_id="B5" value="69.4" spread="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides Concentration</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="160"/>
                    <count group_id="B3" value="325"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="981"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137.3" spread="77.3"/>
                    <measurement group_id="B2" value="150.6" spread="154.6"/>
                    <measurement group_id="B3" value="145.9" spread="67.5"/>
                    <measurement group_id="B4" value="139.7" spread="64.9"/>
                    <measurement group_id="B5" value="143.1" spread="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-density Lipoprotein Cholesterol (HDL-C) Concentration</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="160"/>
                    <count group_id="B3" value="325"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="981"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.3" spread="11.9"/>
                    <measurement group_id="B2" value="49.9" spread="15.2"/>
                    <measurement group_id="B3" value="46.5" spread="11.5"/>
                    <measurement group_id="B4" value="47.6" spread="12.3"/>
                    <measurement group_id="B5" value="47.6" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Very Low-density Lipoprotein Cholesterol (VLDL-C) Concentration</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="164"/>
                    <count group_id="B2" value="160"/>
                    <count group_id="B3" value="325"/>
                    <count group_id="B4" value="332"/>
                    <count group_id="B5" value="981"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" spread="14.9"/>
                    <measurement group_id="B2" value="28.4" spread="16.2"/>
                    <measurement group_id="B3" value="28.7" spread="12.6"/>
                    <measurement group_id="B4" value="27.8" spread="12.7"/>
                    <measurement group_id="B5" value="28.1" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" spread="3.48"/>
                    <measurement group_id="O2" value="0.99" spread="3.31"/>
                    <measurement group_id="O3" value="-65.35" spread="3.09"/>
                    <measurement group_id="O4" value="-69.05" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-70.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-75.43</ci_lower_limit>
            <ci_upper_limit>-65.16</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-70.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-74.67</ci_lower_limit>
            <ci_upper_limit>-65.41</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in LDL-C at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.10" spread="3.66"/>
                    <measurement group_id="O2" value="2.63" spread="3.41"/>
                    <measurement group_id="O3" value="-64.66" spread="3.20"/>
                    <measurement group_id="O4" value="-62.30" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-71.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-77.61</ci_lower_limit>
            <ci_upper_limit>-65.93</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-64.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69.97</ci_lower_limit>
            <ci_upper_limit>-59.89</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="4.1"/>
                    <measurement group_id="O2" value="-8.8" spread="4.0"/>
                    <measurement group_id="O3" value="-64.6" spread="3.6"/>
                    <measurement group_id="O4" value="-71.9" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-62.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.2</ci_lower_limit>
            <ci_upper_limit>-56.9</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-63.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.4</ci_lower_limit>
            <ci_upper_limit>-57.8</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="4.2"/>
                    <measurement group_id="O2" value="-7.3" spread="4.1"/>
                    <measurement group_id="O3" value="-63.9" spread="3.7"/>
                    <measurement group_id="O4" value="-66.1" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-63.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69.7</ci_lower_limit>
            <ci_upper_limit>-57.6</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-58.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.3</ci_lower_limit>
            <ci_upper_limit>-53.3</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="3.05"/>
                    <measurement group_id="O2" value="0.33" spread="2.95"/>
                    <measurement group_id="O3" value="-56.57" spread="2.70"/>
                    <measurement group_id="O4" value="-59.08" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-60.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.51</ci_lower_limit>
            <ci_upper_limit>-56.29</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-59.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.52</ci_lower_limit>
            <ci_upper_limit>-55.29</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-HDL-C at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-HDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.87" spread="3.20"/>
                    <measurement group_id="O2" value="1.30" spread="3.03"/>
                    <measurement group_id="O3" value="-55.76" spread="2.79"/>
                    <measurement group_id="O4" value="-52.92" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-61.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-66.82</ci_lower_limit>
            <ci_upper_limit>-56.45</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-54.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.70</ci_lower_limit>
            <ci_upper_limit>-49.74</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B100 at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B100 at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="3.31"/>
                    <measurement group_id="O2" value="-1.52" spread="2.99"/>
                    <measurement group_id="O3" value="-54.96" spread="3.07"/>
                    <measurement group_id="O4" value="-56.37" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.93</ci_lower_limit>
            <ci_upper_limit>-52.93</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-54.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.52</ci_lower_limit>
            <ci_upper_limit>-51.18</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B100 at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B100 at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" spread="3.42"/>
                    <measurement group_id="O2" value="-0.26" spread="3.03"/>
                    <measurement group_id="O3" value="-53.90" spread="3.14"/>
                    <measurement group_id="O4" value="-49.68" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-57.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.59</ci_lower_limit>
            <ci_upper_limit>-52.54</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-49.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.31</ci_lower_limit>
            <ci_upper_limit>-45.53</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="2.30"/>
                    <measurement group_id="O2" value="-0.25" spread="2.18"/>
                    <measurement group_id="O3" value="-38.64" spread="2.04"/>
                    <measurement group_id="O4" value="-39.74" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-41.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.95</ci_lower_limit>
            <ci_upper_limit>-38.10</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-39.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.47</ci_lower_limit>
            <ci_upper_limit>-36.53</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" spread="2.40"/>
                    <measurement group_id="O2" value="0.67" spread="2.24"/>
                    <measurement group_id="O3" value="-37.82" spread="2.10"/>
                    <measurement group_id="O4" value="-35.22" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-42.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.02</ci_lower_limit>
            <ci_upper_limit>-38.42</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-35.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.12</ci_lower_limit>
            <ci_upper_limit>-32.67</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="2.38"/>
                    <measurement group_id="O2" value="-2.03" spread="2.41"/>
                    <measurement group_id="O3" value="-41.06" spread="2.11"/>
                    <measurement group_id="O4" value="-45.70" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-44.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.64</ci_lower_limit>
            <ci_upper_limit>-40.54</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-43.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.90</ci_lower_limit>
            <ci_upper_limit>-40.44</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="2.49"/>
                    <measurement group_id="O2" value="-1.22" spread="2.47"/>
                    <measurement group_id="O3" value="-40.72" spread="2.18"/>
                    <measurement group_id="O4" value="-41.78" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-43.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.90</ci_lower_limit>
            <ci_upper_limit>-39.97</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-40.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.08</ci_lower_limit>
            <ci_upper_limit>-37.04</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="3.30"/>
                    <measurement group_id="O2" value="-1.02" spread="3.09"/>
                    <measurement group_id="O3" value="-55.60" spread="3.07"/>
                    <measurement group_id="O4" value="-57.75" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-58.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.15</ci_lower_limit>
            <ci_upper_limit>-54.25</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-56.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.53</ci_lower_limit>
            <ci_upper_limit>-52.93</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23" spread="3.39"/>
                    <measurement group_id="O2" value="-0.10" spread="3.16"/>
                    <measurement group_id="O3" value="-54.98" spread="3.12"/>
                    <measurement group_id="O4" value="-51.80" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-58.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.59</ci_lower_limit>
            <ci_upper_limit>-53.84</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-51.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.81</ci_lower_limit>
            <ci_upper_limit>-47.59</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)</title>
        <time_frame>Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)</title>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" lower_limit="15.9" upper_limit="28.7"/>
                    <measurement group_id="O2" value="19.4" lower_limit="13.9" upper_limit="26.3"/>
                    <measurement group_id="O3" value="90.1" lower_limit="86.2" upper_limit="92.9"/>
                    <measurement group_id="O4" value="91.3" lower_limit="87.6" upper_limit="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel Haenszel test stratified by entry statin therapy and geographic region.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>68.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>60.4</ci_lower_limit>
            <ci_upper_limit>74.8</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel Haenszel test stratified by entry statin therapy and geographic region.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>71.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>64.1</ci_lower_limit>
            <ci_upper_limit>77.9</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With LDL-C Less Than 70 mg/dL (1.8 mmol/L) at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With LDL-C Less Than 70 mg/dL (1.8 mmol/L) at Week 12</title>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" lower_limit="15.2" upper_limit="28.2"/>
                    <measurement group_id="O2" value="21.3" lower_limit="15.5" upper_limit="28.6"/>
                    <measurement group_id="O3" value="88.2" lower_limit="84.0" upper_limit="91.4"/>
                    <measurement group_id="O4" value="90.2" lower_limit="86.2" upper_limit="93.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel Haenszel test stratified by entry statin therapy and geographic region.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>67.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58.9</ci_lower_limit>
            <ci_upper_limit>73.9</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel Haenszel test stratified by entry statin therapy and geographic region.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>68.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>60.6</ci_lower_limit>
            <ci_upper_limit>75.3</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.89" spread="17.49"/>
                    <measurement group_id="O2" value="8.48" spread="9.49"/>
                    <measurement group_id="O3" value="-38.63" spread="13.67"/>
                    <measurement group_id="O4" value="-42.29" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-55.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-92.64</ci_lower_limit>
            <ci_upper_limit>-18.40</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.82</ci_lower_limit>
            <ci_upper_limit>-37.72</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein(a) at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein(a) at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.53" spread="21.78"/>
                    <measurement group_id="O2" value="7.47" spread="10.40"/>
                    <measurement group_id="O3" value="-35.93" spread="16.47"/>
                    <measurement group_id="O4" value="-37.85" spread="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-62.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>24.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-110.89</ci_lower_limit>
            <ci_upper_limit>-14.03</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-45.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.87</ci_lower_limit>
            <ci_upper_limit>-28.77</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.54" spread="5.27"/>
                    <measurement group_id="O2" value="8.48" spread="4.48"/>
                    <measurement group_id="O3" value="-6.48" spread="4.70"/>
                    <measurement group_id="O4" value="-7.15" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-18.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.89</ci_lower_limit>
            <ci_upper_limit>-10.14</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-15.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.69</ci_lower_limit>
            <ci_upper_limit>-9.58</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.50" spread="5.36"/>
                    <measurement group_id="O2" value="8.07" spread="4.57"/>
                    <measurement group_id="O3" value="-5.91" spread="4.75"/>
                    <measurement group_id="O4" value="-4.24" spread="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-16.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.63</ci_lower_limit>
            <ci_upper_limit>-8.19</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-12.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.76</ci_lower_limit>
            <ci_upper_limit>-5.86</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="2.19"/>
                    <measurement group_id="O2" value="5.88" spread="2.11"/>
                    <measurement group_id="O3" value="7.59" spread="1.99"/>
                    <measurement group_id="O4" value="13.75" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>6.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.36</ci_lower_limit>
            <ci_upper_limit>9.33</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>7.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.10</ci_lower_limit>
            <ci_upper_limit>10.65</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in HDL-C at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in HDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="2.29"/>
                    <measurement group_id="O2" value="6.04" spread="2.18"/>
                    <measurement group_id="O3" value="8.45" spread="2.04"/>
                    <measurement group_id="O4" value="14.18" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>5.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.49</ci_lower_limit>
            <ci_upper_limit>9.27</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>8.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.03</ci_lower_limit>
            <ci_upper_limit>11.25</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo QM</title>
            <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.63" spread="4.70"/>
                    <measurement group_id="O2" value="7.92" spread="4.43"/>
                    <measurement group_id="O3" value="-17.55" spread="4.19"/>
                    <measurement group_id="O4" value="-16.09" spread="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-27.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.20</ci_lower_limit>
            <ci_upper_limit>-20.17</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab Q2W - Placebo Q2W</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, entry statin therapy and geographic region, scheduled visit, and the interaction of treatment with scheduled visit</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-24.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.88</ci_lower_limit>
            <ci_upper_limit>-18.14</ci_upper_limit>
            <estimate_desc>Treatment difference = Evolocumab QM - Placebo QM</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug to 30 days after last dose; up to 14 weeks.</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo QM</title>
          <description>Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Evolocumab Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Evolocumab QM</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster cutaneous disseminated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

